OBJECTIVES: Lung cancer is the leading cause of death in cancer statistics throughout developed countries. While single surgical approach provides best results in early stages, multimodality approaches have been employed in advanced disease and demonstrated superior results in selected patients. With either full-dose chemotherapy and/or radiotherapy, patients usually have a poor general condition when entering surgical therapy and therefore neoadjuvant therapy can lead to a higher morbidity and mortality. Especially in the case of pneumonectomy as the completing procedure, mortality rate can exceed over 40%. Therefore, chest physicians often shy away from recommending pneumonectomy as final step in trimodal protocols. We analysed our experience with pneumonectomy after neoadjuvant chemoradiotherapy in advanced non-small-cell lung cancer (NSCLC) with a focus on feasibility, outcome and survival.
INTRODUCTION
Lung cancer is the leading cause of death in cancer statistics [1] throughout developed countries. The overall 5-year survival rate across all stages is 17% and treatment options are of wide range. For early stage disease, surgery is well accepted as the first therapeutic option. Anatomical resections are standard procedures and pneumonectomy is regarded as a major procedure with a perioperative mortality rate around 6-12% [2, 3] and can involve limited quality of life.
Despite all progress of the last decades, the 5-year survival rate in Stage III non-small-cell lung cancer (NSCLC) disease is numbered <20% [4] and multimodal protocols were implemented to improve outcome. Treatment-related burden is high in these multimodal approaches and patients suffering from sequelae of full-dose chemo-or chemoradiotherapy when entering surgical therapy. Wound healing of human tissue, especially bronchial tissue, is thought to be affected. Therefore, major procedures such as pneumonectomy are regarded with an even higher risk of morbidity and mortality. In literature, mortality rate is listed up to exorbitant 26-43% [5, 6] . In consequence, oncologists and chest physicians shy away recommending pneumonectomy as a completing procedure for locally advanced NSCLC, even it seems to be the only curative option.
We conducted a retrospective study about feasibility of pneumonectomy after trimodal therapy for locally advanced NSCLC with regard to survival over a 17-year time span.
METHODS

Study design
A retrospective single-centre cohort analysis was conducted. The Institutional Review Board of Tuebingen University waived approval and individual consent. Follow-up was taken from our own outpatient files and with survival check of central registry office in Baden-Württemberg, Germany. The cut-off date for follow-up was August 2010. Complete follow-up was defined either as dead at cut-off date or alive at cut-off date with proofed sign of live within 1 year of cut-off date. Sign of live was taken either by our own outpatient files or by check at registry office in Baden-Württemberg, Germany.
Study population
Oncologic staging was based on 6th edition of TNM in lung cancer.
Included were all patients between 1989 and October 2006 with previously untreated NSCLC, following neoadjuvant radiochemotherapy and having had lobectomy, bi-lobectomy or pneumonectomy. Inclusion criteria for neoadjuvant therapy were clinical Stage III NSCLC, ECOG performance scale of 0-2 and technically resectable disease after chemoradiotherapy.
Detailed oncological staging protocol has already published elsewhere [7, 8] .
Functional staging
All patients had spirometry, body plethysmography and ECG. Pulmonary diffusion capacity (DLCO) was available and routinely performed since 2003. Since 2005, spiroergometry was routinely applied to determine peak oxygen consumption (VO 2 peak). All efforts ( physiotherapy, pharmacotherapy) to improve lung function during neoadjuvant radiochemotherapy were done. Patients were eligible for surgery if forced expiratory volume after 1 s (FEV1) was >70% and DLCO >60%.
A perfusion scan of the lung was done to estimate postoperative FEV1 and DLCO if FEV1 was <70% or DLCO <60%. Operation was declined if postoperative FEV1 or postoperative DLCO was <40%. With VO 2 peak levels <10 ml/kg/min, operation was declined. If VO 2 peak level was <20 ml/kg/min, patients were usually accepted only for lobectomies.
Neoadjuvant protocol
Neoadjuvant protocol Nr. 1 from 1989 to 1998 consisted of two courses of cisplatin (100 mg/m 2 ) and vindesine (3 mg/m 2 ) and subsequent sequential standard fractionated (2 Gy/day) radiation up to 36 Gy to the tumour and mediastinum and two additional concurrent courses of cisplatin and vindesine.
From 1998, we used neoadjuvant protocol Nr. 2 with four courses polychemotherapy applying carboplatin, area under curve 2 (AUC2) and paclitaxel (100 mg/m²) once weekly. Subsequently, accelerated hyperfractionated radiotherapy with two treatments per day (1.5 Gy) on a daily basis (five times per week) and a cumulative dose of 45 Gy was initiated on Week 6. Radiotherapy targeted at tumour, mediastinum and supraclavicular region with a margin of 1.5 cm. Two additional concurrent cycles of chemotherapy [carboplatin (AUC2) and paclitaxel (50 mg/m²)] were administered.
After complete restaging without re-mediastinoscopy, operation had been performed if R0-resection seems feasible.
Statistical analysis
All statistical calculations were performed with the SPSS Statistics 19.0 software package, SPSS Inc. in Chicago, IL, USA.
The Kaplan-Meier method was used to analyse median survival after operation. Risk factors for survival, including pneumonectomy, right-sited procedure, T-stage, ypT-stage, N-stage, ypN-Stage and ypUICC, were analysed using the log-rank test (univariate testing) and Cox regression.
For the Cox regression and univariate testing, staging variables were categorized as follows: T-stage in T1, T2, T3 and T4; ypT-stage in ypT1, ypT2, ypT3 and ypT4; N-stage in N0, N1, N2 and N3; ypN-stage in ypN0, ypN1, ypN2 and ypN3 and finally yUICC were categorized in yUICC0, yUICCIa, yUICCIb, yUICCIIa, yUICCIIb, yUICCIIIa, yUICCIIIb and yUICCIV.
The χ 2 test was used for comparing qualitative variables. For comparing quantitative variables, unpaired t-test was used in the case of normal distribution and the Mann-Whitney U-test in others.
RESULTS
A total of 171 patients between 1988 and 2006 received neoadjuvant therapy for Stage III NSCLC and were operated on. Seven patients showed Stage IV disease and 18 patients had an explorative thoracotomy without resection and were excluded from further analysis. One hundred and forty-six patients (118 men, 28 women) were included in this study. Fifty patients were treated with neoadjuvant protocol nr. 1 and 96 were treated with protocol nr. 2 for 90 right-sited and 56 left-sited tumours. Total follow-up was 6091 months or 507 years. Follow-up was complete for 114 patients (93 dead and 21 still alive). From the remaining 32 patients with incomplete follow-up, 14 patients were lost in follow-up after 60 months postoperatively and 18 (5.6%) patients were lost in follow-up before reaching margin of 5 postoperative years.
Pretherapeutic UICC-and TNM-stages are listed in Table 1 . Sixty-two lobectomies, 6 bi-lobectomies and 78 pneumonectomies were done for 138 R0 and 8 R1 resections. Forty-one patients had a sleeve resection (19 bronchial sleeve, 9 vascular sleeve, 3 bronchial and vascular sleeve and 10 carinal resection) and 60 patients needed extended resection (25 partial left atrial resection, 14 chest wall resection, 14 partial oesophagectomies, 3 replacements of vena cava superior, 3 resection of diaphragm and 1 aortic replacement). Histological analysis showed 85 squamous cell carcinomas, 45 adenocarcinomas, 12 adeno-squamous mix tumours and 4 large cell carcinomas.
Pathological staging after trimodal therapy is listed in Table 2 . All Stage IV were separate tumours in a different lobe on the same site.
Regression grade after trimodal therapy according to Junker et al. [9] was full with no residual vital tumour tissue in 33 (22.6%), <10% vital tumour tissue in 52 (35.6%), more than 10% in 50 (34.2%) and no regression at all in 4 (2.7%) patients. In seven (4.7%) patients, a histological assessment of regression was not possible.
Between the groups with pneumonectomy vs. lobectomy/ bi-lobectomy, no statistical difference concerning age at operation, body mass index, FEV1%, RV% VCin%, PaO 2 , PaCO 2 , gender and postoperative morbidity were found. Only TLC% and distribution of right-sited tumours showed a significant difference between the two groups (Table 3) .
Our treatment-related comorbidity rate was 53%, including bleeding, re-operation due to any reason, bronchus stump insufficiency, cardiac infarction, cardiac arrest, lung embolism, any new neurological disorders, renal insufficiency, atelectasis with bronchoscopic intervention, pneumonia, empyema, respiratory insufficiency, adult respiratory distress syndrome and acute lung injury. In the case of pneumonectomy, morbidity rate was 56 and 48% after lobectomy/ bi-lobectomy.
Overall 30-day mortality rate was 2.7% (n = 4), hospital mortality rate was 4.8% (n = 7) and 90-day mortality rate was 7.5% (n = 11). All early deaths within 30 days had a pneumonectomy. In the case of lobectomy, 30-day mortality, hospital mortality and 90-day mortality were 0, 3.2 (n = 2) and 7.3% (n = 5), respectively. After pneumonectomy, 30-day mortality, hospital mortality and 90-day mortality were 5.1 (n = 4), 6.4 (n = 5) and 7.7% (n = 6), respectively.
Survival
Overall median survival rate was 31 months with a 5-year survival rate of 39% (Fig. 1) . While lobectomy/bi-lobectomy showed a median and 5-year survival rate of 55 months and 45%, the group having had pneumonectomy showed a median survival of 26 months and a 5-year survival rate of 33% (Fig. 2) . Median survival after right-sited pneumonectomy was 26 vs. 31 months after left-sited pneumonectomy, respectively (Table 4) .
Pneumonectomy was not a risk factor for survival (P = 0.48) using univariate log-rank test. Within the group of pneumonectomy, right-sited procedures also had no significance survival benefit with P = 0.72.
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COMMENT
In 2008, 150 000 people in the USA and 340 000 people in Europe died [1, 10] of NSCLC. For that reason, lung cancer is the leading cause of death in cancer statistics in men and women with increasing numbers [1] . Prognosis strongly depends on extend of the disease when first diagnosed and the available therapeutic options. In early stage disease, surgical therapy with complete resection provides best chances for healing. Standard procedures like lobectomy or pneumonectomy with mortality rates of 1% in the case of lobectomy and up to 12% [3] for pneumonectomy provide a 5-year survival rate of 60-80% depending on population and staging options [11] . Clinical Stage III, advanced disease, represents the most heterogeneous group with 12 TNM subsets and an overall 5-year survival rate between 7 and 18% [4] . Not surprisingly, there is no single ideal therapeutic approach. Many protocols with single and multimodality methods are employed with a range from supposed curative to a clear palliative intention. It is known that neoadjuvant multimodal therapy can be superior in selected patients with excellent results [7] , but there is still an ongoing controversy about the cardinal benefit and optimal protocol since only few prospective studies [12, 13] have shown an overall superiority and several others failed [14, 15] . Another critical aspect of trimodal therapy is well-known comorbidity [16] . Neoadjuvant protocols are presumed to cause an increasing rate of wound-healing disorders because human tissue can be affected by chemoradiotherapy and patients suffer from sequelae of radiochemotherapy showing poor general condition when entering surgical therapy. Time of recovery can be prolonged, the patients need more assistance and a higher rate of treatment-related morbidity and mortality is expected. Even without oncological pretreatment, pneumonectomy is considered a major procedure with elevated mortality rates and should be reserved to experienced surgeons [3] but in the case of neoadjuvant approaches, especially with both, chemo-and radiotherapy, a mortality rate of exorbitant 43% is reported [6] . Hence, a lot of oncologists and chest physicians shy away from recommending pneumonectomy as the completing procedure, even against their better knowledge that achieving R0-situation, if technical and functional feasible, can provide better outcome.
We, as well as all thoracic surgeons, avoid pneumonectomy whenever possible and the use of 28% sleeve resections after chemoradiotherapy demonstrates the surgical challenge to keep the rate of pneumonectomy as low as possible. In fact, pretreatment with chemoradiotherapy aims a downstaging effect for a better resectability but often only leads to a clinical downsizing effect. Therefore and because of a high rate of central T4-tumours in our population, pneumonectomy with additional extended resections of adjacent structures as only curative surgical option is needed in more than half of our patients. With 53% rate of pneumonectomy for Stage III disease, we achieve an overall 5-year survival rate of 38% (Fig. 1) , which is higher than average survival rates of around 20% in Stage III NSCLC reported by Goldstraw et al. [4] . This fact may be due to selection criteria, but we also see a successful and notable improvement of outcome by the trimodal approach.
Overall treatment-related comorbidity after trimodal protocol was 53% showing the remarkable burden to the patients and the challenge for all participating clinical disciplines. Despite the extended rate of morbidity, our overall 30-day mortality rate and hospital mortality rate remain acceptable with 2.5 and 5.1%, respectively. After pneumonectomy, 30-day mortality rate and hospital mortality rate were 5.1 and 6.4%, respectively, which is still low in neoadjuvant treatment compared with others [5, 17, 18] . A closer look to the early deaths within 30 days reveals that all (n = 4) of them had a pneumonectomy, one patient died from bronchus stump insufficiency, another two died from acute respiratory distress syndrome/sepsis and one from cardiac arrest. Despite follow-up showed no statistical significance for pneumonectomy as a risk factor (P = 0.48), 30-day mortality risk with 5.1% after pneumonectomy vs. 0% in the group of lobectomy is clearly higher and shows that patients after pneumonectomy can be at higher risk because of acute cardiopulmonary disorders, but mortality rate after discharge is already adjusted with 5.1 vs. 3.2%, respectively. After 90 days, we had further harmonization of mortality rate throughout all analysed groups. In our study, it does no't matter whether the patients had lobectomy, pneumonectomy or right-sited pneumonectomy, mortality rate remains around 8% after trimodal therapy for Stage III NSCLC. Our data show that experienced centres can handle side effects of neoadjuvant trimodal therapy, including pneumonectomy without an exorbitant increasing mortality rate.
Beneath comorbidity and mortality, survival after neoadjuvant therapy for Stage III NSCLC is the most valued argument pro or contra neoadjuvant therapy protocols. Interestingly, the overall survival curve shows a period between 20 and 70 months after operation with a clear advantage in favour of patients having had lobectomy. The difference culminates around 50-60 months, but at the end, the survival curves come together and there is only a tendency in our study for a better survival after lobectomy. The difference is, in contrary to others [6, 17, 19] , not statistically significant. This may be due to less statistical power and need not necessarily stay in contrast to others, but due to our experience, we cannot approve pneumonectomy as a risk factor for survival after trimodal therapy in Stage III NSCLC.
Another issue when discussing pneumonectomy as a risk factor is the supposed higher risk for right-sited procedures [20, 21] . We did 42 right-sited and 36 left-sited pneumonectomies after neoadjuvant chemoradiotherapy with a median survival time of 26 and 31 months after right-and left-sited procedure, respectively, and we found only a trend towards longer survival in the case of left-sited procedure with no significant statistical difference (P = 0.72).
To our understanding beneath a thorough oncological staging, a very experienced team of physicians and thorough physical therapy of a rigorous and comprehensive functional staging after chemoradiotherapy and immediate before surgery is mandatory and crucial for achieving low mortality rates after trimodal therapy. The patients' general condition has to be brought at its best after chemoradiotherapy and if they cannot fulfil functional criteria for a pneumonectomy because of sequelae of radiochemotherapy, we either allow them some more time to recover or strictly deny surgery. Possible disadvantage from this strategy is an advanced cicatrization after radiotherapy, which can challenge the surgeon.
Another interesting aspect is the fact that initial T-, N-or UICC-stage, when NSCLC was first diagnosed, lost their prognostic value. Only pathological T-(P < 0.001), N-(P = 0.001) and UICC-stage (P < 0.001) after trimodal therapy regain their prognostic significance (Table 5) .
Genuine downstaging effect was seen in 72% and full response rate with no detectable vital tumour could have been proved in 23%. This demonstrates a high rate of response by the chosen neoadjuvant protocol. In consequences, as long as oncologists and chest physicians cannot precisely predict response rates in advance, they should carefully select patients for a clear palliative approach, as R0 resection sometimes can only be estimated after radiochemotherapy by experienced thoracic surgeons. Therefore, precociously denying surgery or a neoadjuvant approach in Stage III NSCLC, even in the case of necessitating pneumonectomy may not be best choice as long as neoadjuvant protocol is similar to full-dose radiochemotherapy.
In conclusion, pneumonectomy after neoadjuvant chemoradiotherapy and R0 surgery for Stage III NSCLC can provide superior survival rates in selected patients. Even a necessary pneumonectomy for completing trimodal therapy protocol in Stage III NSCLC can be done safe and with acceptable mortality rate in the case of experienced facilities and thoracic surgeons. Oncologists and chest physicians should not shy away to recommend patients pneumonectomy in trimodal therapy for Stage III disease.
APPENDIX. CONFERENCE DISCUSSION
Dr S. Bolukbas (Wiesbaden, Germany): This paper demonstrates that, in selected patients, aggressive protocols, including surgery, might have a benefit for patients with stage III non-small cell lung cancer. However, I have one question. You showed us your workup of your patients including CT scans of all sites, PET, PET-CT and mediastinoscopy, and in your methodology you showed us that you excluded N3 disease, supraclavicular and hilar. However, you had a number of N3 patients.
Dr Steger (Tubingen, Germany): Yes, we had Dr Bolukbas: Was it due to your complete mediastinal lymph node assessment, or how do you explain it?
Dr Steger: You mean how we included N3 patients initially? Dr Bolukbas: Not initially, but afterwards. You excluded N3 patients but you found N3 patients.
Dr Steger: Yes, we had N3 patients. That's because we had the 6th version of the UICC where contralateral paratracheal is labelled N3 in these patients and we have some in this analysis. We analysed it, but there is no difference between these patients. The only patients we have excluded after radiochemotherapy were contralateral N3 and supraclavicular active N3.
Dr F. Detterbeck (New Haven, CT, USA): I think this illustrates an important point, that sometimes we don't pay enough attention to. The quality of how things are done has a big effect. We had a staging paper earlier where I think the quality of how that is done is important. I think quality of the perioperative management of patients is important, and I think that when we talk about the role of trimodality therapy for stage III non-small cell lung cancer, I think that has become very important. It is clear, as this paper shows and as a number of other papers show, that although pneumonectomy in the setting of trimodality therapy can be a cause of mortality that is very high and can offset any benefit, that isn't necessarily true, and that the centre that it is done in, if that is a centre that has experience and does it well, it can be very different. Where it is done and how those patients are managed, and knowing your ability to get people through, is a very important factor that is often not appreciated enough.
Dr B. Witte (Koblenz, Germany): My question just goes in the direction of the remark Frank Detterbeck has already made. Your lethality and morbidity is fivefold lower than in published evidence from the last decade. So how do you explain this? What are you doing differently? Selection, treatment?
Response by Volker Steger, Tübingen, Germany. Dr Steger: We are not doing anything different. It is a real experience involving the whole staff, not an effort from the surgeons alone; an anesthesiologist is involved, the nurse is involved. These patients are a challenge to the whole staff in our hospital. And if you get enough experience, and we have almost 20 years of experience, we have the level of excellence required to manage these patients with standard complication rates.
Dr Witte: Do you see it dependent on the radiation therapy dose? You started with 33 Gy, then you went to 45, but there are even protocols that offer definitive radiotherapy up to 60 or 70 and then go on to resection for very responsive patients.
Dr Steger: I am not an expert in radio oncology, but I was told this kind of therapy is strongly dependent on the volume and can exceed in standard fractionation up to 90 Gy if you have normal values. So if you do a hyper fractional accelerated rate of therapy with this kind of therapy, you have almost the same achievement of 70 to 90 Gy in standard fractionation, and we have no problem with that more than we had before with 30 Gy standard radiation.
